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Abstract
Background: Obstructive sleep apnea (OSA) is severely affected by visceral adiposity (VA) that correlates to another
disorder—metabolic syndrome (MetS). However, little is known concerning the relation of visceral adiposity index
(VAI)—a novel and simple indicator of VA, with OSA and MetS. The objective of the study was to analyze the
association of VAI with both disorders and applicability to identify OSA patients at risk of MetS.
Methods: Consecutive individuals undergoing polysomnography and biochemical tests were enrolled, and differences
in all subjects grouped by apnea-hypopnea index (AHI) were analyzed. Spearman correlation was performed for
assessing the relationship between VAI, OSA-related indices and metabolic score—total number of the positive
diagnostic criteria of MetS. Receiver operating characteristic (ROC) curve was conducted to obtain a cut-off value
of VAI for predicting incident MetS by sex. Then, the risk of MetS in OSA patients according to the cut-offs was
attained by logistic regression.
Results: A total of 411 individuals were enrolled. Of whom, 361 subjects were diagnosed OSA (mild in 67
patients, moderate in 89 and severe in 205, respectively). A significant increasing trend based on AHI was
observed in the variables of blood pressure, triglycerides, fasting glucose, incident MetS, metabolic score and VAI
(all p < 0.05). Irrespective of gender, VAI was all significantly correlated with PSG characteristics as AHI, mean
nocturnal oxygen saturation, the lowest oxygen saturation, metabolic score(all p < 0.05). A VAI of 2.282, 2.105,
2.511 (for all subjects, males and females, separately) were calculated to determine the occurrence of MetS.
According to the cut-offs, OSA patients tended to suffer from greater risk in MetS (odds ratio [OR] = 10.237,
p = 0.000; OR = 13.556, p = 0.000; OR = 21.458, p = 0.000).
Conclusions: The present study suggested that VAI was significantly associated with MetS and OSA. As a simple
and alternative approach obtained in everyday practice, it may offer a powerful tool to identify patients with OSA
at risk of MetS.
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Background
Obstructive sleep apnea (OSA) is a highly prevalent
disorder with 23.4–49.7 % of the general population. It
refers to repetitive events of partial or complete upper
airway occlusion during sleep, leading to recurrent
oxyhemoglobin desaturations [1]. OSA is mainly deter-
mined by visceral adiposity that correlates to another
disorder—metabolic syndrome (MetS) [2, 3]. MetS,
with a prevalence of 22.8 % of men and 22.6 % of women
in general population, is recognized as a constellation
of visceral obesity, glucose intolerance, dyslipidemia and
hypertension [4]. It predisposed patients to the develop-
ment of cardiovascular diseases (CVD) and diabetes [5].
To our knowledge, there is growing amount of evidence
on the relationship of OSA with MetS [6, 7].
Visceral adiposity, accurately estimated by computed
tomography (CT), has been confirmed to be an import-
ant contributor for not only MetS but also [2, 3, 8] OSA.
Meanwhile, regardless of at a similar body mass index
(BMI) or waist circumference (WC), Chinese individuals
are prone to have a greater amount of visceral adipose
tissue than Europeans [9]. Thus, visceral adiposity index
(VAI) as a reliable surrogate gender-specific indicator of
adipose tissue function and distribution, which comprises
simple anthropometric (BMI and WC) and metabolic
(triglycerides (TG) and high density lipoprotein-cholesterol
(HDL-C)) markers, is implicated in insulin sensitivity, MetS
and cardio-metabolic diseases [10–12].
To date, little information is available regarding the
relation between VAI and OSA. Recently, one study
demonstrated the link between MetS and VAI in OSA
patients. It was reported that VAI progressively increased
with insulin resistance (IR) and metabolic score, unfortu-
nately, it did not predict sleep apnea severity, suggesting
that VAI was a good marker of MetS, but not of OSA
[13]. On the other hand, the applicability of VAI in early
determining cardio-metabolic risk, particularly in those
subjects who did not have overt MetS, has been described
in several studies [14–16]. VAI was superior to other
metabolic markers in discriminating metabolism abnor-
malities, adipokine secretion and adipose tissue distri-
bution [17, 18].
The aim of the current study was to explore whether
VAI was closely associated with both OSA and MetS,
and to further test the applicability of VAI in predicting
MetS in OSA patients, improving the management of
the complication of OSA.
Method
Study population
From January 2011 to December 2014, a total of 411 in-
dividuals, who were on admission to our sleep center
with the complaints suggestive of nocturnal hypopnea,
were retrospectively analyzed. These subjects completed
a detailed questionnaire containing histories of current
smoking and illness, medical treatment including medi-
cations for hypertension and hypertriglyceridemia, hypergly-
cemia prior to the study, and they underwent an overnight
polysomnography (PSG). According to self-reported medical
histories, patients who were excluded met the criterion
below: 1. chronic obstructive pulmonary disease; 2. Asthma;
3. Cerebrovascular disease; 4. Congestive heart failure; 5.
Symptomatic ischemic heart disease; 6. Chronic renal
failure; 7. Rheumatologic diseases and Hypothyroidism.
Those previously diagnosed or treated for OSA were
also excluded. The research was approved by the Ethics
Committee of the First Affiliated Hospital of Fujian
Medical University. All patients provided written informed
consent to participate in this study.
Anthropometric and clinical assessment
The details of demographic parameters including age,
gender, WC, height, weight and blood pressure (BP) were
obtained. Weight and height were measured, with subjects
in light clothing without shoes in a standing position while
shoulders were in a normal alignment. And BMI was
calculated based on the equation—weight is divided by
the square of height (kg/m2). WC was measured at the
umbilical level. After a 5-min interval, two measurements
of BP were taken by well-trained physicians, on the right
arm, using a standardized mercury sphygmomanometer in
the sitting position; Then, the average was described in
the data analysis. Venous Blood was drawn after 12-h
fasting period for measurement of fasting glucose (FG),
HDL and TG using the Modular P800 auto-analyze
(Roche, Tokyo, Japan). VAI, a sex-specific index based
on WC, BMI, TG and HDL-C, was obtained using the
following equations [10]: Males: VAI = (WC/(39.68 +
(1.886BMI)))*(TG/1.03)* (1.31/HDL). Females: VAI =
(WC/(36.58 + (1.896BMI)))* (TG/0.81)* (1.52/ HDL).
Definition of metabolic syndrome
Patients were diagnosed MetS based on the NCEP ATP
III modified criteria [7] which describes a combination
of at least three components of the five abnormalities: 1)
waist circumference ≥90 cm for men and ≥80 cm for
women of Asian; 2) a serum triglycerides ≥1.7 mmol/L
or the use of medication for dyslipidemia; 3) HDL <
40 mg/dL for men and <50 mg/dL for women or the use
of medication for low HDL; 4) a recorded arterial BP ≥130
or ≥85 mmHg for systolic and diastolic BP separately ac-
cording to the average of two consecutive measurements,
or the use of antihypertensive medication; 5) FG level ≥
5.6 mmol/L or the use of diabetes medication. The meta-
bolic score was determined as the sum of the positive
MetS diagnostic criteria for each participant.
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Polysomnography evaluation
A full-night PSG (P Series Sleep System; Compumedics;
Melbourne, Australia) monitoring recorded parameters
as follows: electroencephalogram, oculogram, chin and
bilateral anterior tibials electromyogram, electrocardiogram,
nasal airflow, chest and abdominal movement, pulse
oxygen saturation, snoring, and body position. All trac-
ings were scored manually according to the guideline of
the American Academy of Sleep Medicine (AASM) in
2007 [19]. Apnea was defined as a complete cessation
(≥90 %) from baseline in airflow of ≥10s and hypopnea
as a drop (≥30 %) in airflow of ≥10s accompanied by
oxygen desaturation ≥4 %. Apnea-hypopnea index (AHI)
was expressed as a total number of episodes of obstructive
apneas plus hypopneas per hour during sleep. Oxygen de-
saturation index (ODI) was attained from the frequency of
desaturations of ≥4 % per hour. The percentage of sleep
duration with SpO2 < 90 % (TS90 %), and lowest O2 satur-
ation (LaSO2), mean oxygen saturation (mean SpO2) were
also recorded. Subjects were classified into four groups ac-
cording to AHI. OSA was defined as absent, mild, moder-
ate and severe when AHI was < 5/h, 5–14.9/h, 15–29.9/h,
and > 30/h, respectively.
Statistics analysis
All analyses were conducted using SPSS version 20.0
(SPSS Inc., Armonk, NY, USA). All variables were assessed
for normality by Kolmogorov–Smirnov test. Skewed con-
tinuous variables presented as the median and interquar-
tile range (IQR) and were analyzed by Kruskal–Wallis H.
Normally distributed data presented as mean ± SD were
analyzed by Student’s t test or one-way ANOVA for com-
parison. Categorical variables were presented as number
(percentage), applying the chi-square test or Fisher’s exact
test when compared. Spearman correlation was performed
for assessing the relationship between VAI, metabolic
score and OSA-related hypoxemia indices. Variables that
did not have a normal distribution were log-transformed.
We conducted receiver operating characteristic curve
(ROC) and calculated the area below the curves with a
95 % confidence interval. A cut-off value of VAI by sex
for predicting the presence of MetS was attained. After-
wards, a binary logistic regression was performed to
analyze the risk of incident MetS in OSA patients based
on VAI’s cut-off points. A two-tailed value of p < 0.05
was thought to be significant.
Results
A total of 411 individuals, including 312 males and 99
females, were enrolled in the study. Their BMI were
26.49 ± 3.03 kg/m2, ages were 48.80 ± 13.62 years. Of
whom, 361 subjects were found AHI ≥ 5/h, with mild in
67 patients, moderate in 89 and severe in 205, respect-
ively. The demographic and polysomnographic parameters
of all subjects according to AHI are detailed in Table 1.
No differences could be found for age, current smoking or
medical treatment, whereas gender was significantly dif-
ferent among groups. WC, BMI, AHI, ODI and TS90 %
progressively increased across AHI categories, while mean
SpO2, LaSO2 decreased significantly (all p < 0.001).
The metabolic characteristics of the participants are
shown in Table 2. A significant increasing trend based
on AHI was observed in the variables of SBP, TG, FG,
uric acid (UA), incident MetS, metabolic score and VAI
(all p < 0.05). Conversely, a significantly negative associ-
ation of AHI with HDL-C was presented (p = 0.000).
Table 3 shows the correlations between VAI, OSA-
related parameters and other metabolic variables. Irre-
spective of gender, VAI was all significantly correlated
with WC, BMI, AHI, mean SpO2, LaSO2, HDL-C and
UA (all p < 0.05). Unfortunately, the significant associ-
ation of VAI with other indices did not existed concern-
ing TS90 %, SBP, FG, TG in females and ODI, DBP in
males. A VAI of 2.282, 2.105, 2.511(for all subjects, males
and females) were calculated from ROC curves to deter-
mine the occurrence of MetS in OSA patients. The related
sensitivity and specificity by sex are detailed in Figs. 1, 2
and 3. The area under the ROC curve of VAI was 0.836
(0.797–0.875), 0.838 (0.792–0.883), 0.826 (0.736–0.916)
(all p < 0.001). According to the cut-offs, OSA patients
were prone to get involved in significantly greater risk in
incident MetS, with logistic regression after adjusting
confounders such as age and current smoking (odds
ratio [OR] = 10.237, p = 0.000; OR = 13.556, p = 0.000;
OR = 21.458, p = 0.000).
Discussion
This cross-sectional study demonstrated that there were
significant differences in terms of OSA-related indices,
UA, incidence of MetS, metabolic score and VAI grouped
by AHI. Spearman correlation illustrated that regardless
of gender, VAI was all significantly correlated with PSG
characteristics as AHI, mean SpO2, LaSO2 and metabolic
indicators as UA. Particularly, the correlation of VAI
with metabolic score existed. Further, all suspected
OSA patients or by sex according to certain cut-offs of
VAI were prone to get involved in MetS (OR = 10.237,
p = 0.000; OR = 13.556, p = 0.000; OR = 21.458, p = 0.000,
respectively).
It has been emphasized that there is a high co-
prevalence rate of OSA and MetS [20, 21]. As eluci-
dated, OSA was closely correlated with typical features
of the MetS, i.e. IR and accumulation of visceral adipose
tissue (VAT) [3, 8, 22]. Numerous studies in obese pa-
tients [2, 3, 8, 22] with OSA have shown that VA is sig-
nificantly higher than BMI—matched controls. Indeed,
excess VA was strongly associated with the presence and
severity of apnea, especially in males [22]. Likewise,
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Table 1 The anthropometric and polysomnographic parameters of all patients according to the severity of OSA
AHI (0-5) AHI (5-15) AHI (15-30) AHI (30-) P
Subjects 50 67 89 205
Age, years 44.36 ± 16.18 49.70 ± 11.64 49.72 ± 12.98 49.45 ± 13.62 0.105
Male sex, number (%) 30 (60 %) 41 (61.19 %)***** 69(77.52 %) 172(83.9 %)***, ***** 0.000
Current smoking,
number (%)
6(12 %) 12(17.91 %) 19(21.35 %) 44(21.46 %) 0.445
Antilipimic agents,
number (%)
2(4 %) 3(4.48 %) 4(4.49 %) 14(6.83 %) 0.772
Antidiabetic agents,
number (%)
1(2 %) 4(5.97 %) 6(6.74 %) 16(7.80 %) 0.522
Antihypertensive
agents, number (%)
8(16 %) 12(17.91 %) 27(30.34 %) 56(27.32 %) 0.108
Waist circumference (cm) 88.70 ± 10.35**, *** 90.43 ± 8.79****, ***** 94.58 ± 8.43**, ****, ****** 98.26 ± 10.27***, *****, ****** 0.000
BMI (kg/m)2 23.94 ± 3.03**, *** 24.98 ± 3.25***** 25.94 ± 3.69**, ****** 27.84 ± 5.93***, *****, ****** 0.000
AHI 2.14(0.80-4.25)*, **, *** 9.30(7.20-12.30)*, ****, ***** 21.30(18.25-24.25)**, ****, ****** 52.40(40.95-65.45)***, *****, ****** 0.000
Mean SpO2 (%) 96.50 (95.00-97.00)**, *** 96.00(95.00-96.00)***** 95.00(94.00-96.00)**, ****** 92.00(88.00-94.00)***, *****, ****** 0.000
LaSO2 (%) 90.00(84.75-92.00)**, *** 86.00(80.00-88.00)****, ***** 79.00(75.00-85.50)**, ****, ****** 67.00(57.00-78.00)***, *****, ****** 0.000
TS90% (%) 0.00(0.00-0.36)**, *** 0.18(0.02-0.78)***** 0.98(0.10-2.57)**, ****** 7.60(2.71-17.93)***, *****, ****** 0.000
ODI 1.50(0.50-3.40)**, *** 6.30(3.40-9.40)****, ***** 15.54(9.58-19.95)**, ****, ****** 46.20(31.60-62.40)***, *****, ****** 0.000
Normally distributed data (age, waist circumference, BMI) were expressed as mean ± SD skewed data (including, AHI, ODI, TS90 %, LaSO2, mean SpO2) were presented as median (interquartile range). Categorical
variables were expressed as number (percentage), OSA obstructive sleep apnea, BMI body mass index, AHI apnea-hypopnea index; mean SpO2: mean nocturnal oxygen saturation, LaSO2 lowest O2 saturation, TS90%
the percentage of sleep duration with SpO2 < 90 %, ODI oxygen desaturation index; *: if P < 0.05 between group 0 [AHI (0-5)] and group 1 [AHI(5-15)]; **: if P < 0.05 between group 0 [AHI (0-5)] and group 2
















despite of similar BMI and WC, Vgontzas et al. revealed
that LaSO2 during sleep was independently associated
with VAT, which was in agreement with us expressed by
VAI(Table 3) [3]. Further evidence was provided by
LaSO2 which significantly predicted IR [23], supporting
that LaSO2 may be one of the underlying promoters in
inducing lipid abnormality [24]. On the other hand, as
discussed by Shah et al. in 1,511 individuals, different
impact of visceral fat assessment by CT on MetS risk
existed. Irrespective of BMI, initial VA and change in VA
were associated with MetS. Dynamic inspection in VA
may be predictive in the target of therapy in cardio-
metabolic diseases [2]. Collectively, visceral obesity/IR
may be the principal determiners, progressively leading
to the exacerbation of MetS and OSA. Meanwhile, pro-
gressive deterioration of OSA may accelerate worsening
VA and MetS with nocturnal elevations of hormones,
such as cortisol and insulin.
VAI, a simple indicator strongly correlated with VA,
was obtained from several metabolic parameters. It is
suggestive of a possible ‘adipose tissue dysfunction’ and
the risk of IR, MetS and CVD in populations without an
overt MetS [10, 11, 15, 16, 25]. The current data regard-
ing whether VAI is a reliable parameter of OSA severity
remain conflicting. Significances could be found in VAI
among groups classified by AHI, irrespective of gender.
Furthermore, significant correlations were displayed in
Table 3 Spearman’s rank correlation coefficients between VAI
and polysomnographic and metabolic characteristics
Log VAI (All) Log VAI (Male) Log VAI (Female)
β p β p β p
Log AHI 0.272 0.000 0.219 0.000 0.401 0.000
Log mean SpO2 −0.178 0.000 −0.160 0.005 −0.215 0.032
Log LaSO2 −0.165 0.001 −0.160 0.005 −0.272 0.007
Log TS90% 0.157 0.001 0.129 0.023 0.187 0.064
Log ODI 0.282 0.000 0.035 0.695 0.410 0.000
Log SBP 0.113 0.000 0.120 0.172 0.245 0.014
Log DBP 0.171 0.000 0.141 0.014 0.187 0.064
UA 0.305 0.000 0.261 0.000 0.368 0.000
Log FG 0.487 0.002 0.107 0.059 0.266 0.008
TG 0.897 0.000 0.897 0.000 0.930 0.000
Log HDL-C −0.667 0.000 −0.660 0.000 −0.778 0.000
Log metabolic score 0.698 0.000 0.694 0.000 0.674 0.000
VAI visceral adiposity index, AHI apnea-hypopnea index, mean SpO2 mean
nocturnal oxygen saturation, LaSO2 lowest O2 saturation, TS90% the percentage
of sleep duration with SpO2< 90 %, ODI oxygen desaturation index, SBP/DBP
systolic/diastolic blood pressure, UA uric acid, FG fasting glucose, TG triglycerides,
HDL-C high-density lipoprotein-cholesterol
Table 2 The metabolic and biochemical characteristics of all patients according to the severity of OSA
AHI (0-5) AHI (5-15) AHI (15-30) AHI (30-) P
SBP (mmHg) 120.00(110.00-130.00)*** 120.00(117.00-138.00) 128.00 (120.00-140.00) 130.00 (120.00-140.00)*** 0.005
DBP (mmHg) 80.00(71.50-80.00)*** 78.00(70.00-80.00)***** 80.00(76.00-84.50) 80.00 (77.00-88.00)***, ***** 0.005
HDL-C (mmol/L) 1.28 (1.01-1.54)*** 1.19(1.03-1.47)***** 1.16 (0.93-1.37) 1.04(0.91-1.26)***, ***** 0.000
Fasting glucose (mmol/L) 5.02(4.54-5.54)*** 5.02(4.73-5.82) 5.16(4.76-5.68) 5.33(4.91-6.00)*** 0.008
Triglycerides (mmol/L) 1.61 ± 1.07*** 1.66 ± 0.89***** 1.76 ± 1.14****** 2.32 ± 1.94***, *****, ****** 0.001
Uric acid (mmol/L) 350.66 ± 97.10*** 336.24 ± 103.99****, ***** 378.12 ± 96.41****, ****** 407.98 ± 103.36***, *****, ****** 0.000
Hypertension, number (%) 30(60 %)*** 40(59.7 %) 66(74.16 %) 157(76.59 %)*** 0.014
Hypertriglyceride mia,
number (%)
16(32 %)*** 25(37.31 %)***** 34(38.20 %)****** 114(56.10 %)*****, ****** 0.001
Hyperglycemia, number (%) 11(22 %) 21(31.34 %) 28(31.46 %) 76(37.07 %) 0.188
Low HDL-C, number (%) 15(30 %)*** 25(37.31 %) 36(40.45 %) 105(51.22 %)*** 0.017
Central obesity, number (%) 31(62 %)**, *** 54(80.60 %) 73(82.02 %)** 175(85.37 %)*** 0.003
Metabolic syndrome,
number (%)
16(32 %)*** 34(50.74 %) 48(53.93 %) 140(68.29 %)*** 0.000
Metabolic score 2.00 (1.00-3.00)*** 3.00(2.00-3.00)***** 3.00(2.00-4.00) 3.00(2.00-4.00)***** 0.000
VAI (All) 1.46 (0.99-2.75)*** 1.90(1.25-2.89)***** 1.93(1.25-3.01)****** 2.53(1.70-3.79)*****, ****** 0.000
VAI (Male) 1.62(1.41-4.11) 2.04(1.50-2.95) 1.94(1.26-2.93) 2.52(1.61-3.74) 0.027
VAI (Female) 1.19(0.71-2.35) 1.52(0.93-2.83) 1.80(0.94-3.74) 2.54(1.82-4.32) 0.001
Normally distributed data (triglycerides, uric acid) were expressed as mean ± SD skewed data (including SBP/DBP, HDL-C, fasting glucose, metabolic score, VAI)
were presented as median (interquartile range). Categorical variables were expressed as number (percentage). OSA: obstructive sleep apnea, SBP/DBP systolic/
diastolic blood pressure, HDL-C high-density lipoprotein-cholesterol, VAI visceral adiposity index. *: if P < 0.05 between group 0 [AHI (0-5)] and group 1 [AHI(5-15)]; **: if
P < 0.05 between group 0 [AHI (0-5)] and group 2 [AHI(15-30)]; ***: if P < 0.05 between group 0 [AHI (0-5)] and group 3[AHI(30-)]; ****: if P < 0.05 between group 1 and
group 2; *****: if P < 0.05 between group 1 and group 3; ******: if P < 0.05 between group 2 and group 3
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VAI and OSA-related variables (Table 3). In contrast,
gender-specific research inferred that VAI increased with
IR linking with VA, and it was not predictive of OSA
[13]. Mazzuca et al. suggested gender-related interac-
tions between OSA, VA and metabolic abnormalities,
unfortunately, VAI was not a good indicator of OSA
Notably, VA increased with OSA severity, and the sig-
nificant effects of ethnicity on VA have been extensively
investigated. East Asians have the most deleterious ab-
dominal fat distribution [9], particularly, in Asian women
[26]. Excess VA and OSA are often related conditions, and
they seem to interact with each other in a vicious circle.
Although VAI was not a gold standard for VA, VAI may
change in line with the increase in VA to some degree.
This discrepancy may be attributed to differences in the
races, the OSA criterion and higher BMI in their study
[13]. As far as we were concerned, VAI reflected accur-
ately the degree of VA and IR [13, 18, 27]. Further, in a
cohort study [18] enrolling 308 adult Saudi subjects,
metabolic, hormonal parameters and circulating concen-
trations of several circulating adipokines such as adipo-
nectin, leptin were examined. VAI was finally identified
as the sole determinant of adiponectin, one of the chief
players in the MetS progress [28]. The fact that VAI is
related only with adiponectin levels may account for the
detrimental role of VA in the loss of defensive mecha-
nisms and the occurrence of cardio-metabolic dysfunc-
tion. It should be emphasized that Chinese individuals are
predisposed to have more VA than Westerners, which
suggests an increased risk of metabolic abnormalities [9].
Compared with other metabolic biomarkers, VAI, which
combined both physical and metabolic parameters, was
better in identifying metabolism abnormalities and ab-
dominal obesity instead of MRI and CT [10, 14]. More-
over, regardless of the ability of CT as the gold standard in
discriminating fat distribution, it could not be easily ap-
plicable in population and clinical practice due to high
cost and radiation [29]. Application of VAI may be of
clinically importance and public health implications in
the management of MetS.
Though we have shown that the metabolic score in-
creased with the exacerbation of OSA, which was in line
with many researchers [6, 20], interestingly, metabolic
score and VAI had the strongest correlation with the
polysomnographic indices of ODI in our study. It may re-
mind us the key impact of oxyhemoglobin desaturations
Fig. 1 ROC curves for prediction of the presence of MetS in all subjects with suspected OSA. The area under ROC curves was observed for visceral
adiposity index. (AUC = 0.836, 95 % CI: 0.797–0.875, p = 0.000). A VAI of 2.282 had a sensitivity of 68.5 % and a specificity of 86.7 % in determining the
occurrence of MetS. ROC: Receiver operating characteristic; MetS: metabolic syndrome; OSA: obstructive sleep apnea; AUC: area under curve;
CI: confidence interval. VAI: visceral adiposity index
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on the metabolism [30]. It was possible that oxyhemoglo-
bin desaturations affected VAI more than apnea or hypop-
nea. Caution should be paid that focusing on nocturnal
oxygen would be beneficial to the prevention of these
diseases.
The impact of OSA on inflammatory markers in con-
secutive patients with MetS has been reported. Mean-
while, accumulation of VAT has been associated with an
increase in interleukin-6, tumor necrosis factor-a, hs-CRP,
and a decrease in adiponectin in obese patients [31]. Also,
available information supported the positive correlation
between TNF and VAI [32], implying a role of VAI in pro-
inflammatory activity. Besides, the strongest association
between VAT with hyperuricemia was clearly in favor of
us (Table 3) [33]. Increased UA levels have been shown to
play a mechanistic role in inflammation and antioxidation
in the environment of obesity, which may in turn promote
lipid oxidation [34]. The close relation between VAI and
UA indicated that VAI could be also used to predict
inflammation and metabolism, which was confirmed by
the dose–response relationship of UA with MetS [35]. In
addition, hyperinsulinemia would contribute to hyperuri-
cemia and hypertension [36], resulting in an increased risk
of metabolic abnormality.
Consistent with our findings (Table 3), the significant
link of VAI with both prehypertension and hypertension
was observed [37]. Despite of the absence of the BP fac-
tor in the calculation of VAI, it still could be utilized as
an effective biomarker for monitoring hypertension. Pre-
vious studies have emphasized the clinical importance of
the applicability of VAI in predicting MetS [14, 16]. Not-
ably, they drew more attention to the correlation of VAI
with some components of MetS [16]. By contrast, on the
basis of OSA, we explored the indicative role of VAI in
the occurrence of MetS. Early stages of MetS may be not
highlighted by the classic criteria. However, VAI, seems to
be able to indicate early metabolic risk in patients without
overt MetS by suggesting continuous changes. Moreover,
Fig. 2 ROC curves for prediction of the presence of MetS in males with OSA. The area under ROC curves was observed for visceral adiposity index.
(AUC = 0.838, 95 % CI: 0.792–0.883, p = 0.000). A VAI of 2.105 had a sensitivity of 73.3 % and a specificity of 82.1 % in determining the occurrence of
MetS. ROC: Receiver operating characteristic; MetS: metabolic syndrome; OSA: obstructive sleep apnea; AUC: area under curve; CI: confidence interval.
VAI: visceral adiposity index
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different from the fact that diagnosis of MetS should be in
accordance with three or more components, VAI was
obtained from an equation. Thus, a combination of VAI
and NHANES-ATP III criteria could estimate metabolic
abnormality in OSA patients complementarily. Further, it
was important to point out that the occurrence of MetS
was associated to the development of CVD and diabetes
mellitus type 2 in teenagers and adults [38, 39]. As shown
[38], the MetS was responsible for 2.6–3.0 times higher
CVD mortality. Appropriate stratified-for-age cut-off
point of VAI from a large cross-sectional study was
able to identify a supposed adipose tissue dysfunction
associated with CVD [15]. Similarly, we determined
the risk of MetS according to VAI cut-offs by sex, es-
pecially in OSA patients. As displayed in Table 4, we
implied that females would be disposed to greater risk
of MetS than males, although excess VA was more
strongly associated with apnea, especially in males. Early
recognition, prevention of metabolism abnormalities in
OSA patients would improve the management of these
disorders.
Some limitations of our study still need to be eluci-
dated. First, due to the cross-sectional design, we were
unable to determine a direct causal relationship between
OSA and metabolic abnormalities. Likewise, the statistical
power of VAI to predict the MetS in OSA patients may be
Table 4 Odds ratio for MetS in OSA patients according to the
cut-off of VAI
Factor OR 95%CI p
VAI (All) 10.237 5.842-19.939 0.000
VAI (Male) 13.556 7.563-24.298 0.000
VAI (Female) 21.458 6.940-66.345 0.000
According to the cut-off of VAI, OSA patients above the cut-offs tended to
suffer from significantly greater risk in incident MetS, with logistic regression
after adjusting confounders such as age, current smoking. R2 for entire
model = 0.333, 0.367, 0.460 (for all subjects, males and females, respectively),
CI confidence interval, OR odds ratio, MetS metabolic syndrome, OSA obstructive
sleep apnea, VAI visceral adiposity index
Fig. 3 ROC curves for prediction of the presence of MetS in females with OSA. The area under ROC curves was observed for visceral adiposity index.
(AUC = 0.826, 95 % CI: 0.736–0.916, p = 0.000). A VAI of 2.511 had a sensitivity of 68.2 % and a specificity of 90.9 % in determining the occurrence of
MetS. ROC: Receiver operating characteristic; MetS: metabolic syndrome; OSA: obstructive sleep apnea; AUC: area under curve; CI: confidence interval.
VAI: visceral adiposity index
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insufficient. Second, IR was not measured, therefore we
could not directly examine the associations of VAI with IR
which was strongly associated with VA and inflammation
[40]. Third, we failed to consider the menopausal status,
which may lead to some bias in final inferences. Increases
in VAT were supposed to be associated with menopausal
transition and the ages [41, 42], however, relatively little of
the variance in VAT (or VAT%) was due to the independ-
ent effect of menopausal status [42]. Well designed stud-
ies, including strict exclusion for menopausal women, are
needed to figure out the exact association between VAI,
OSA and MetS. Forth, significances in the gender propor-
tion among groups existed, which may affect some infer-
ences after statistics analysis. However, we analyzed the
role of VAI by sex, making a contribution to a compre-
hensive understanding on these disorders. Finally, differ-
ences from previous reports in geographical and ethnically
diverse populations, in part, attenuated these concerns.
Conclusion
Overall, VAI was significantly associated with MetS and
OSA. As a simple and alternative approach obtained in
everyday practice, VAI may offer a powerful tool to iden-
tify patients with OSA at risk of MetS.
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